Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

77 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-02

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs.

The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways.

Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interstitial Lung Disease in Early Rheumatoid Arthritis

NCT03977415

Rheumatoid Arthritis Interstitial Lung Disease

UNKNOWN

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

NCT03297775

Rheumatoid Arthritis Interstitial Lung Disease

RECRUITING

Early Rheumatoid Arthritis Lung Disease Study

NCT03192267

Rheumatoid Arthritis

RECRUITING

dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound

NCT06235645

Rheumatoid Arthritis Interstitial Lung Disease Thoracic Ultrasound +1 more

RECRUITING

Feasibility of a Cytokine Expression Profile in Immune Cells as an Orientation Tool in Therapeutic Decisions for Auto-inflammatory and Auto-immune Diseases

NCT03280797

Rheumatoid Arthritis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Descriptive

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with rheumatoid arthritis ACR/EULAR 2010
* Patient with a higher age or equal to 18
* Patient receiving social security
* Patient giving his free and informed written consent

Exclusion Criteria

* Patient with overlap syndrome with another autoimmune disease
* Patients with known severe cardiopulmonary pathology
* Woman who is pregnant and breast feeding
* Patient with language difficulties or understanding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No